We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Ovarian Tissue Transplant Helps Cancer Survivors Maintain Fertility

By HospiMedica International staff writers
Posted on 18 Oct 2015
A new study suggests that cryopreservation of ovarian tissue in female cancer survivors is an effective and safe way to maintain fertility.

Researchers at Rigshopitalet University Hospital (Copenhagen, Denmark), Aarhus University Hospital (Denmark), and other institutions conducted a retrospective cohort study of 41 women who received a total of 53 transplants of cryopreserved ovarian tissue between 2003 and 2014; mean age at time of cryopreservation was 29.8 years, and all but two of the women had an entire ovary cryopreserved. More...
The women were followed with regular clinical visits after transplantation.

Once the ovarian tissue was transplanted back, the levels of follicle-stimulating hormone (FSH) and luteinizing hormone returned to normal after 4-5 months. One of the women, a prepubertal girl who was 13.8 years old at time of transplantation, succeeded in having puberty induced. The researchers found that the functional life span of the grafts has been greater than 10 years for two patients, greater than 7 years in 3 patients, greater than 4 years in 7 patients, between 2 and 4 years in 15 patients, between 1 and 2 years in 7 patients, and less than a year in 6 patients.

In all, 24 clinical pregnancies were established in the 32 women with a pregnancy-wish, with an overall 30% success rate. Of these, 10 succeeded in birthing one or more children, including one woman with a third trimester on-going pregnancy. In addition, two legal abortions and one second trimester miscarriage occurred. Three cancer relapses also occurred, but according to the researchers were unlikely to be due to the transplanted tissue. The study was published on August 24, 2015, in Human Reproduction.

“Many girls and young women who have been diagnosed with a disease such as cancer now have a realistic hope of recovery and living a normal life, but the treatment for their disease can cause infertility by damaging the functioning of their ovaries,” concluded lead author Annette Jensen, PhD, of the University of Copenhagen in Denmark, and colleagues. “Fertility preservation is increasingly becoming an integral part of treatment. However, as ovarian transplantation is still in its early days, its efficacy and safety need to be investigated.”

“Neither age at cryopreservation, age at first transplantation, amount of tissue grafted, nor the follicular density of the grafted tissue proved to predict successful conception,” added the researchers. “We hope that our results will enable this procedure to be regarded as an established method in other parts of the world, which has an important implication on how it is funded and reimbursed.”

Cryopreservation is a process wherein cells, whole tissues, or any other substances susceptible to damage caused by chemical reactivity or time are preserved by cooling to sub-zero temperatures so as to stop enzymatic activity. By default it should be considered that cryopreservation alters or compromises the structure and function of cells, unless it is proven otherwise for a particular cell population.

Related Links:

Rigshopitalet University Hospital 
Aarhus University Hospital



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
New
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.